Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | BHMT | Q93088 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23336392 | 0.84 | BHMT (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4BHMT | |
| SCHEMBL20691201 | 0.82 | SLC6A19 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4BHMT | |
| SCHEMBL31335959 | 0.81 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17120398 | 0.81 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20093382 | 0.81 | ALDH1A1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4BHMT | |
| SCHEMBL7928560 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27451892 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20425354 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15829888 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23049192 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | CHRNB2 4086/4885CHRNB4 3402/4885CHRNA3 3438/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | CHRNB2 4559/4885CHRNB4 3689/4885CHRNA3 4223/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CHRNB2 4305/4885CHRNB4 4361/4885CHRNA3 3268/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | CHRNB2 4085/4885CHRNB4 3120/4885CHRNA3 3281/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | CHRNB2 4085/4885CHRNB4 3120/4885CHRNA3 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.